Chordate Medical's two incentive programs fully subscribed by the board and management

26 May 2023 - 15:10

The two incentive programs that were decided by Chordate Medical’s general meeting on May 11th, 2023, have today been signed in full by the company's board and management. This involves the subscription of 4,000,000 warrants of series 2023/2025:1, and thus an increase in the share capital by SEK 1,000,000, as well as 1,500,000 warrants of series 2023/2025:2, and thus an increase in the share capital by SEK 375,000.

The purpose of the incentive programs is that current and future employees and consultants in the Company will be able to become long-term shareholders and work for, and take part of, a positive value development of the share in the Company during the period covered by the proposed program, and that Chordate Medical will be able to retain and recruit competent and committed staff.

Provided by: MFN
Nasdaq First North GM Stockholm (Sweden)
Chordate Medical Holding AB
Chordate Medical develops treatments for chronic nasal congestions through physical vibration. The vibration stimulates the nervous system, which in turn contracts the blood vessels in the nasal mucosa, which facilitates and creates space for air....
Learn more about company

Related news

We use cookies to make your experience using IPOhub better. By using our site you agree to our use of cookies. Learn More